GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of 1 of the following:

  * Solid tumor malignancy (phase I only)\*
  * Prostate cancer (phase I only)\*
  * Non-small cell lung cancer (phase I and II)\*
* Recurrent, metastatic, locally advanced unresectable, or treatment-refractory disease
* Measurable disease

  * At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  * Previously irradiated lesions are considered measurable provided they have demonstrated progression before study entry
  * No bone-only disease

    * Must have measurable disease other than bone lesions
* No stage IIIA or IIIB non-small cell lung cancer without a malignant pleural or pericardial effusion that is eligible for first-line radical combined chemotherapy and radiotherapy
* No known progressive or symptomatic brain metastases

  * Asymptomatic brain metastases allowed
* Performance status - ECOG 0-2
* Performance status - Karnofsky 60-100%
* More than 3 months
* WBC at least 3,000/mm\^3
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* No history of coagulopathy
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* AST/ALT no greater than 2 times ULN (3.5 times ULN if liver metastases are present)
* INR no greater than 1.3
* APTT no greater than 1.25 times ULN
* Creatinine no greater than 1.5 times ULN
* Creatinine clearance at least 50 mL/min
* No symptomatic congestive heart failure
* No evidence of cardiac dysfunction
* No unstable angina pectoris
* No cardiac arrhythmia
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No active peptic ulcer disease
* No poorly controlled diabetes mellitus
* No pre-existing grade 2 or greater neuropathy
* No ongoing or active infection
* No contraindication to corticosteroids
* No psychiatric illness or social situation that would limit compliance with study requirements
* No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
* No other concurrent uncontrolled illness
* One, and only one, prior chemotherapy regimen for advanced disease (not including adjuvant therapy) allowed

  * Neoadjuvant/adjuvant chemotherapy allowed
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered
* Prior multiple lines of endocrine therapy for advanced solid tumors allowed
* More than 4 weeks since prior endocrine therapy and recovered
* Concurrent steroids allowed
* See Disease Characteristics
* More than 4 weeks since prior radiotherapy and recovered
* No concurrent radiotherapy to sole site of measurable disease
* Prior surgery allowed
* No concurrent anticoagulant therapy

  * Concurrent low-dose warfarin for central line thrombosis prophylaxis allowed
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational or commercial agents or therapies intended to treat the malignancy
* Concurrent bisphosphonates allowed